Exhibit 3.
Average Quarterly Spending On And Use Of Oral Oncologics Available In The US Market, First Quarter 2006 Through Third Quarter 2011
| Category | Estimated percent
|
|||||
|---|---|---|---|---|---|---|
| Spending ($US 2012)
|
Use (extended units)
|
|||||
| Q1–4 2006 average | Q4 2010–Q3 2011 average | Change | Q1–4 2006 average | Q4 2010–Q3 2011 average | Change | |
| THERAPEUTIC CLASS | ||||||
|
| ||||||
| Alkylating agents | 10.00 | 7.63 | −23.67 | 3.31 | 2.10 | −36.63 |
| Topoisomerase inhibitors | 0.46 | 0.50 | 7.88 | 0.09 | 0.07 | −22.80 |
| Antimetabolites | 11.12 | 12.18 | 9.54 | 18.28 | 17.96 | −1.76 |
| Hormonal agents | 41.82 | 19.13 | −54.26 | 73.04 | 72.79 | −0.34 |
| Targeted agents | 35.26 | 59.32 | 68.26 | 4.41 | 6.32 | 43.11 |
| Other | 1.35 | 1.25 | −7.80 | 0.86 | 0.76 | −11.31 |
|
| ||||||
| PATENT PROTECTION STATUS DURING STUDY PERIOD | ||||||
|
| ||||||
| Patent protected throughout | 45.30 | 72.87 | 60.86 | 11.65 | 15.11 | 29.61 |
| Lost patent protection | 37.38 | 13.19 | −64.72 | 26.39 | 30.64 | 16.12 |
| Generic throughout | 7.41 | 3.26 | −56.01 | 61.96 | 54.36 | −12.43 |
|
| ||||||
| FEE-FOR-SERVICE MEDICARE OUTPATIENT COVERAGE | ||||||
|
| ||||||
| Medical benefit (Part B) | 18.95 | 18.51 | −2.33 | 7.62 | 6.84 | −10.34 |
| Pharmacy benefit (Part D) | 81.05 | 81.49 | 0.54 | 92.38 | 93.16 | 0.85 |